

Equity Market Overview

Q3 2026 EQUITY MARKET HIGHLIGHTS

**Back to School Jitters – Despite a strong summer, equities sold off in September, traditionally a challenging month for stocks, leaving major indices with mixed quarterly returns**

- The S&P 500 and Nasdaq eked out quarterly gains driven by mega-cap Technology stocks while the Dow ended with a modest loss. However, all major indices are still up YTD.
- Small-cap stocks were the biggest underperformers, battered by rising yields. Notably, both the S&P SmallCap 600 and Russell 2000 Equal Weight indices underperformed their respective counterparts, indicating that larger constituents held up better than the median small-cap stock.
- Energy maintained its lead as the S&P 500's best-performing sector due to elevated oil prices as tensions with the Middle East continue. Technology was the second-best sector despite continued AI concerns as mega-cap Technology stocks and AI-linked names proved resilient despite volatility.

**The Good, the Bad and the Ugly – Chipmakers and mega-cap growth stocks led gains late in the quarter despite rising Treasury yields, hawkish Fed comments, persistent inflation concerns and geopolitical headlines**

- The Good:** Earnings remain a positive spotlight as companies continue posting resilient results. Despite ongoing valuation concerns, the AI trade regained momentum late in the quarter with semiconductors leading gains as fears of a capital expenditure cliff appeared overblown.
- The Bad:** Market conditions have yet to stabilize as the ongoing US-Iran conflict continues pressuring oil prices while concerns over the scale of AI capex relative to returns remain in focus despite the late-quarter rally.
- The Ugly:** The Fed's first rate hike since 2023, coupled with hawkish commentary, weighed on sentiment as inflation concerns persist. Long-term Treasury yields surged with the 10-year rising above 5% and the 30-year reaching its highest level since 2002, pressuring rate-sensitive sectors and small-cap stocks.


**Looking Backward to Look Forward – Stocks have historically performed well during Q4, with major indices outperforming other quarters on average despite investor uncertainty during election years (see chart below)**

- Looking ahead, the upcoming midterm elections may create near-term volatility, but equities have historically outperformed during this period. According to Bloomberg data, 21 of the last 23 midterm election years produced positive Q4 returns. Although growth stocks have often been pressured around Election Day, risk appetite has historically improved following the vote, supporting stronger performance into year-end.
- While the election may lead to investor uncertainty in October, markets have historically rebounded afterward, with the S&P 500 recovering any pre-midterm weakness within three months of year-end. Over the past two decades, the S&P 500 has generated a median Q4 return of 7.2% during midterm election years.


MARKET PERFORMANCE

Index	Last	3Q26	2Q26	1Q26	YTD	2025 Return
S&P 500	7,651.54	2.0%	(4.6%)	(4.6%)	11.8%	16.4%
S&P 500 EQW	8,429.42	(2.3%)	0.2%	0.2%	8.6%	9.3%
NASDAQ	26,861.06	2.5%	(7.1%)	(7.1%)	15.6%	20.4%
DOW	50,906.05	(2.7%)	(3.6%)	(3.6%)	5.9%	13.0%
Russell 2000	2,796.86	(7.5%)	0.6%	0.6%	12.7%	11.3%
VIX	16.34	(0.7%)	68.9%	68.9%	9.3%	(13.8%)

Q3 S&P 500 SECTOR PERFORMANCE



HISTORIC Q4 EQUITY MARKET RETURNS (2000-2025)



IPO Market Overview⁽¹⁾

Q3 2026 IPO HIGHLIGHTS

**Couldn't Stick the Landing – Despite a solid start to the quarter which saw 20 IPOs raise \$32.8 billion, driven by SK Hynix's jumbo deal, IPO activity stumbled towards the end of the quarter thanks to the broader market environment**

- Excluding SK Hynix's historic IPO, Q3 IPOs raised \$6.3 billion, below historic averages for this period. Amidst the broader market volatility, Q3 IPOs ended with an average (1.4%) total return after rising an average 8.9% on debut. Eight out of the 20 IPOs ended the quarter above issue.
- The Renaissance IPO index fell ~9% but still outpaces the S&P 500 YTD. Including the latest set of deals, 86 IPOs have raised a total of \$149.3 billion YTD, the highest level since 2021 despite the market's challenges. The 2026 class rose an average of 5.1%, and 34 of the 86 IPOs ended the quarter above issue.
- Venture-backed IPOs accounted for ~\$4 billion, driven almost entirely by biotech as traditional tech unicorns were sidelined. Private Equity-backed IPOs accounted for ~\$30 billion, led by SK Hynix and other data center plays, followed by a couple of Consumer IPOs.


**Health is Wealth – Healthcare dominated issuance and delivered the strongest performance, with nine Biotech IPOs averaging 19.7% gains since debut, alongside a surge of issuance from AI infrastructure companies**

- Metabolic disorders biotech Vogenx Inc. drove the sector's outperformance as shares have risen 75.3% since issue. YTD, 26 Healthcare IPOs have raised \$8.3 billion, with the sector rising an average of 37.4%.
- Technology led issuance by proceeds, with two AI infrastructure plays raising \$27.6bn. SK Hynix raised a staggering \$26.5 billion, making it the second-largest IPO in history (behind SpaceX), and data center operator Csquare raised \$1.1 billion. While both traded well initially, persistent AI-related concerns ultimately pressured shares. The quarter also saw the largest direct listing by market cap since 2021 as data center play Ionic Digital listed.

**Failure to Launch – Towards the end of the month, four IPOs delayed their offerings, but the quarter saw 54 new filings as issuers continue monitoring the challenging environment as we head into the final stretch of 2026**

- Historically, midterm election years have constrained the IPO market due to broader market volatility and shorter IPO windows. However, a clear outcome after the election could boost equities and reopen the IPO window for the rest of Q4, consistent with post-election patterns from the past twenty years.
- The pipeline remains robust, driven by large AI-driven filers including SoftBank-backed SB Energy and data center operator Nscale. However, all eyes are on Anthropic's jumbo IPO which is expected to value the company at over \$2 trillion, potentially exceeding SpaceX's record debut, according to Reuters. If successful, the AI giant could reinforce investor risk appetite, though it may overshadow smaller deals.

IPO ISSUANCE BY QUARTER (\$BN)



Q3 2026 IPO ISSUANCE BY SECTOR (\$BN)



FILED & RUMORED IPO PIPELINE



IPO Market Overview⁽¹⁾

20 IPOs GENERATED \$32.8BN

Pricing Date	Issuer Name	Ticker	Sector	Deal Val (ex ovl)	Mkt Val (Pre-Deal)	Offer Price	Range		% Secondary	% Change 1-Day	Offer/Current
							Low	High			
09/29/26	Accelevation Holdings	ACCV	Machinery	\$540.0	\$3,870.0	\$18.00	\$20.00	\$24.00	66.7%	(0.3%)	(0.3%)
09/24/26	ADARx Pharmaceuticals	ADRX	Healthcare	\$446.0	\$1,280.0	\$17.00	\$15.00	\$17.00	–	13.8%	17.3%
09/17/26	Orion180 Insurance Group	OIG	Insurance	\$240.0	\$948.0	\$12.00	\$15.00	\$17.00	–	(2.8%)	(19.7%)
09/17/26	Electra Therapeutics Inc	ETRA	Healthcare	\$350.0	\$592.0	\$15.00	\$14.00	\$16.00	–	(11.7%)	(25.0%)
09/15/26	American Savings Bank	ASBH	Finance	\$129.0	\$1,040.0	\$16.00	\$15.00	\$17.00	100.0%	6.3%	11.8%
08/18/26	Lyntris Inc	LYNX	Aerospace	\$298.0	\$1,929.0	\$17.50	\$19.00	\$22.00	66.4%	(14.2%)	(29.5%)
08/12/26	Robinhood Ventures Fund II	RVII	Finance	\$200.0	\$27.0	\$25.00	\$25.00	\$25.00	–	(8.2%)	(13.8%)
08/11/26	Vogenx Inc	VOGX	Healthcare	\$81.0	\$100.0	\$13.00	\$11.00	\$13.00	–	–	75.3%
08/11/26	Londian Wason New Energy	FOIL	Metal & Steel	\$95.0	\$1,625.0	\$22.00	\$20.00	\$22.00	–	11.4%	(26.1%)
08/06/26	BlossomHill Therapeutics	BLSM	Healthcare	\$150.0	\$340.0	\$16.00	\$15.00	\$17.00	–	–	16.5%
08/06/26	Latigo Biotherapeutics	LTGO	Healthcare	\$346.0	\$795.0	\$18.00	\$16.00	\$18.00	–	1.4%	(7.2%)
08/05/26	Braveheart Bio Inc	BRVE	Healthcare	\$383.0	\$934.0	\$18.00	\$15.00	\$17.00	–	65.6%	12.2%
08/04/26	Attovia Therapeutics	ATTO	Healthcare	\$289.0	\$442.0	\$17.00	\$15.00	\$17.00	–	28.8%	0.8%
07/30/26	Apnimed Inc	APMD	Healthcare	\$192.0	\$448.0	\$16.00	\$14.00	\$16.00	–	56.3%	36.9%
07/29/26	Reformation Inc	REF	Textile	\$211.0	\$744.0	\$15.00	\$15.00	\$17.00	32.6%	0.5%	(19.7%)
07/29/26	Jersey Mike's Subs	JMKE	Dining & Lodging	\$1,000.0	\$8,939.0	\$23.00	\$21.00	\$25.00	68.3%	(6.0%)	(26.9%)
07/23/26	Scribe Therapeutics	SCTX	Healthcare	\$129.0	\$135.0	\$15.00	\$13.00	\$15.00	–	44.3%	22.7%
07/15/26	Standard Nuclear	STDN	Chemicals	\$150.0	\$2,260.0	\$15.00	\$18.00	\$21.00	–	(18.0%)	(21.3%)
07/15/26	Csquare Inc	CSQR	Technology	\$1,050.0	\$2,205.0	\$21.00	\$23.00	\$27.00	–	(1.6%)	(24.7%)
07/09/26	SK Hynix Inc	SKHY	Technology	\$26,507.0	\$1,029,495.0	\$149.00	\$168.06	\$168.06	–	12.8%	(7.4%)
Average (20)				\$1,639.3	\$52,907.4					8.9%	(1.4%)
Median (20)				\$264.5	\$941.0					0.3%	(7.3%)

Follow-On Market Overview⁽¹⁾

Q3 2026 FOLLOW-ON HIGHLIGHTS

**Getting Good Intel – It was another strong quarter of follow-on issuance despite market volatility as 69 deals generated \$39.8 billion in proceeds driven by Intel's jumbo \$20.0 billion offering**

- Excluding Intel's follow-on, the quarter saw \$19.8 billion raised, with the first half of Q3 providing a supportive market backdrop for new issuance. The offerings priced with an average 11.0% discount, in-line with the 10-year average. Issuers rose an average 5.1% one day post-offer but ended the quarter with an average 1.5% loss as equities sold off.
- The period also saw ten selldowns with secondary proceeds accounting for 20% of all follow-on proceeds excluding Intel's deal. A wide variety of sponsors across the Consumer, Technology, Industrials, Healthcare and Finance sectors whittled their stakes during the period. The largest came from Neos Partners' \$2.1 billion selldown in Forgent Power Solutions, marking its third selldown since taking the company public in February.


**The Age of AI – Digital infrastructure expansion accounted for most of the follow-on capital raised, while biopharma led the market in deal count as issuers took advantage of pipeline momentum, regulatory environment and investor demand**

- 34 biopharma follow-ons raised \$6.3 billion, representing 15.8% of total proceeds. Deals priced at an average 8.9% discount, tighter than the broader market, and shares gained an average 2.9% on the first day following pricing. However, a broader market pullback weighed on issuers with the set dropping an average 5.8% by quarter-end.
- Looking ahead, biopharma issuance should remain healthy as growth in GLP-1 and obesity treatments, AI-enabled drug discovery, ongoing M&A activity and increased crossover investor participation continue to support the sector.
- Following Alphabet's blockbuster equity raise in Q2, Intel raised \$20.0 billion through a follow-on offering to fund its semiconductor manufacturing and AI expansion, underscoring continued investment across the AI ecosystem. The landmark transaction accounted for the majority of follow-on proceeds raised during the quarter and ranks as the second-largest US follow-on offering on record, behind Boeing's \$24.3 billion raise in 2024.


**Home Stretch – Although the upcoming midterm elections may introduce near-term volatility, the follow-on market has historically been more resilient than the IPO market, with Q4 often generating the highest issuance volumes of the year**

- A post-election relief rally in November could be a key catalyst for a pickup in larger transactions, as seen in prior midterm years where deal activity accelerated in the final six weeks of the year. Furthermore, despite the recent pullback, companies are entering the last stretch of the year with a constructive backdrop for issuance.


FOLLOW-ON ISSUANCE BY QUARTER (\$BN)



Q3 2026 FOLLOW-ON ISSUANCE BY SECTOR (\$BN)



AVERAGE % FILE / OFFER BY QUARTER



Follow-On Market Overview⁽¹⁾

20 LARGEST FOLLOW-ON OFFERINGS GENERATED \$32.8BN

Pricing Date	Issuer Name	Ticker	Sector	Deal Val (ex ovl)	Mkt Val (Pre-Deal)	Deal Val % Mkt Val	Offer Price	File/ Offer	Last Trade/ Offer	Overnight	% Change 1-Day	Offer/ Current
08/10/26	Intel Corp	INTC	Technology	\$20,000.0	\$491,790.0	4.1%	\$95.00	(6.5%)	(2.6%)	N	2.9%	26.6%
08/05/26	Celestica Inc	CLS	Technology	\$3,000.0	\$41,711.0	7.2%	\$310.00	(14.5%)	(14.5%)	Y	1.5%	2.5%
07/01/26	Forgent Power Solutions	FPS	Machinery	\$2,139.0	\$15,191.0	14.1%	\$49.00	(10.9%)	(1.8%)	N	(4.4%)	(23.6%)
07/07/26	Rivian Automotive Inc	RIVN	Auto/Truck	\$1,163.0	\$22,445.0	5.2%	\$15.50	(23.0%)	(6.0%)	N	7.5%	(3.6%)
07/20/26	Magnolia Oil & Gas	MGY	Oil & Gas	\$1,100.0	\$4,690.0	23.5%	\$23.75	(7.0%)	(7.0%)	Y	5.6%	(1.1%)
09/14/26	SYSCO Corp	SYT	Food & Beverage	\$1,000.0	\$40,063.0	2.5%	\$81.00	(3.0%)	(3.0%)	Y	(1.7%)	(3.8%)
07/01/26	Abivax SA	ABVX	Healthcare	\$800.0	\$10,620.0	7.5%	\$125.00	(6.2%)	(6.2%)	Y	6.1%	(20.2%)
08/10/26	Ryman Hospitality	RHP	Real Estate	\$597.0	\$7,571.0	7.9%	\$117.00	(3.2%)	(2.5%)	N	4.3%	2.2%
07/13/26	Erasca Inc	ERAS	Healthcare	\$550.0	\$5,567.0	9.9%	\$17.50	(2.2%)	(2.2%)	Y	11.4%	(16.2%)
07/16/26	Columbia Financial Inc	CLBK	Finance	\$523.0	\$2,638.0	19.8%	\$10.00	(44.6%)	(56.4%)	N	134.2%	143.3%
09/09/26	Centrus Energy Corp	LEU	Chemicals	\$500.0	\$3,491.0	14.3%	\$199.64	10.0%	10.0%	Y	(16.9%)	(30.1%)
08/19/26	Amylyx Pharmaceuticals	AMLX	Healthcare	\$500.0	\$4,301.0	11.6%	\$35.50	1.1%	(8.0%)	N	11.7%	(18.0%)
08/10/26	Janus Living Inc	JAN	Real Estate	\$464.0	\$8,809.0	5.3%	\$29.00	(3.9%)	(3.9%)	Y	2.0%	2.2%
08/18/26	Alliance Laundry	ALH	Machinery	\$452.0	\$4,692.0	9.6%	\$23.50	(7.7%)	(2.1%)	N	1.9%	(9.4%)
09/14/26	Tyra Biosciences Inc	TYRA	Healthcare	\$400.0	\$1,314.0	30.4%	\$22.03	—	—	Y	13.8%	(0.7%)
08/14/26	BridgeBio Pharma Inc	BBIO	Healthcare	\$390.0	\$15,876.0	2.5%	\$78.00	(4.0%)	-	N	2.4%	(15.6%)
07/21/26	Dyne Therapeutics Inc	DYN	Healthcare	\$375.0	\$3,945.0	9.5%	\$20.50	(14.0%)	(14.0%)	Y	13.2%	(21.4%)
08/04/26	Twist Bioscience Corp	TWST	Healthcare	\$300.0	\$6,233.0	4.8%	\$96.00	(3.5%)	(3.5%)	Y	19.8%	101.3%
09/24/26	Hafnia Ltd	HAFNI	Transportation	\$299.0	\$4,577.0	6.5%	\$80.00	(8.0%)	(8.0%)	Y	5.1%	(87.5%)
09/24/26	Viking Therapeutics Inc	VKTX	Healthcare	\$275.0	\$4,859.0	5.7%	\$35.00	(16.0%)	(16.0%)	Y	5.0%	(6.9%)
Average (20)				\$1,741.4	\$35,019.2	10.1%		(8.4%)	(7.8%)		11.3%	1.0%
Median (20)				\$511.5	\$5,900.0	7.7%		(6.4%)	(3.9%)		5.1%	(5.3%)

Q3 2026 Citizens ECM Update

Q3 2026 CITIZENS EQUITY CAPITAL MARKET HIGHLIGHTS

+\$5 Billion

Raised in Aggregate Proceeds

16

Equity & Equity-Linked Transactions

+\$5 billion

Proceeds Executed by Corporate Services



\$400,000,000

Senior Unsecured
Convertible Notes

Bookrunner

SEPTEMBER 2026



\$240,000,000

Initial Public Offering

Bookrunner

SEPTEMBER 2026



\$550,000,000

Senior Unsecured
Convertible Notes

Bookrunner

SEPTEMBER 2026



\$110,500,000

Follow-On Offering

Bookrunner

SEPTEMBER 2026



\$1,150,000,000

Senior Unsecured
Convertible Notes

Co-Manager

SEPTEMBER 2026



\$150,000,000

Senior Unsecured
Convertible Notes

Bookrunner

AUGUST 2026



\$250,000,000

Senior Unsecured
Convertible Notes

Bookrunner

AUGUST 2026



\$200,000,000

Follow-On Offering

Bookrunner

AUGUST 2026



\$464,000,000

Follow-On Offering

Co-Manager

AUGUST 2026



\$185,000,000

Senior Unsecured
Convertible Notes

Bookrunner

AUGUST 2026



\$500,000,000

Senior Unsecured
Convertible Notes

Co-Manager

AUGUST 2026



\$500,000,000

ATM Offering

Sales Agent

AUGUST 2026



\$75,000,000

ATM Offering

Sales Agent

AUGUST 2026



\$1,000,000,000

Senior Unsecured
Convertible Notes

Co-Manager

AUGUST 2026



\$23,000,000

Follow-On Offering

Lead Bookrunner

JULY 2026



\$1,000,000,000

Senior Unsecured
Convertible Notes

Bookrunner

JULY 2026



\$375,000,000

Senior Unsecured
Convertible Notes

Co-Manager

JULY 2026



\$10,220,000

PIPE Offering

Placement Agent

JULY 2026



\$750,000,000

ATM Offering

Sales Agent

JULY 2026



\$7,500,000,000

ATM Offering

Sales Agent

JULY 2026


CITIZENS OVERVIEW

CITIZENS FINANCIAL GROUP⁽¹⁾

Citizens is one of the oldest and largest financial institutions in the U.S. and currently ranked the 16th largest bank.

CAPITAL MARKETS & ADVISORY⁽²⁾

Capital Markets & Advisory is a fast-growing, full-service investment banking platform that provides capital market access, M&A services and valuation advisory



CITIZENS EQUITY CAPITAL MARKETS

ANDY MERTZ

Managing Director,
Head of Equity Capital Markets
Andrew.Mertz@citizensbank.com

GIANPAOLO ARPAIA

Managing Director,
Head of Equity-Linked Capital Markets
Gianpaolo.Arpaia@citizensbank.com

CLAIRE CORNELL

Director,
Head of Equity Syndicate
Claire.Cornell@citizensbank.com

DANNY MATTHEWS

Director, Head of Healthcare Equity
Capital Markets
Daniel.Matthews@citizensbank.com

CITIZENS CAPITAL MARKETS & ADVISORY OFFICES

SAN FRANCISCO

101 California Street
San Francisco, CA 94111

NEW YORK

1301 Ave of the Americas
New York, NY 10019

BOSTON

28 State Street
Boston, MA 02109

CHICAGO

10 S. Wacker Drive, Suite 1230
Chicago, IL 60606

CORPORATE FINANCE

CAPITAL MARKETS & ADVISORY

TREASURY & RISK MANAGEMENT

©2026 Citizens Financial Group, Inc. "Citizens" is the marketing name for the business of Citizens Financial Group, Inc. ("CFG") and its subsidiaries. "Citizens Capital Markets & Advisory" is the marketing name for the investment banking, research, sales and trading activities of our institutional broker-dealer, Citizens JMP Securities, LLC ("CJMPS"), Member [FINRA](#) and [SIPC](#) (See [FINRA BrokerCheck](#) and [SIPC.org](#)). Securities products and services are offered to institutional clients through CJMPS. ([CJMPS disclosures](#) and [CJMP Form CRS](#)). Banking products and services are offered through Citizens Bank, N.A., Member FDIC.

Securities and investment products are subject to risk, including principal amount invested and are: NOT FDIC INSURED · NOT BANK GUARANTEED · MAY LOSE VALUE